Search results for "Breast Cance"

showing 10 items of 1269 documents

BRCA1 gene-related hereditary susceptibility to breast and ovarian cancer in Latvia

2013

Abstract Purpose In this report, we summarise data on BRCA1 gene analysis in Latvia to characterise criteria of genetic testing for breast and ovarian cancer susceptibility. Material/methods Analysis by SSCP/HD, MALDI-TOF mass spectrometry or DNA sequencing was used for mutation detection. Mutations identified were confirmed by direct DNA sequencing. Results Out of 1068 breast and 231 ovarian cancer patients from different families: 58 carried the c.5266dupC and 43 carried the c.4035delA mutations. Every 4th patient in our study did not report cancer in the family. The breast cancer was diagnosed earlier in carriers of the c.5266dupC than in carriers of the c.4035delA ( p  = 0.003). The inc…

AdultOncologymedicine.medical_specialtyBreast NeoplasmsDiseasemedicine.disease_causePolymerase Chain ReactionBreast cancerInternal medicinemedicineHumansGenetic Predisposition to DiseaseFamily historyskin and connective tissue diseasesPolymorphism Single-Stranded ConformationalAgedGenetic testingAged 80 and overOvarian NeoplasmsMutationmedicine.diagnostic_testBRCA1 Proteinbusiness.industryCancerSingle-strand conformation polymorphismDNA NeoplasmGeneral MedicineMiddle AgedPrognosismedicine.diseaseLatviaMutationFemalebusinessOvarian cancerFollow-Up StudiesAdvances in Medical Sciences
researchProduct

Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer

2003

The chemokine monocyte chemoattractant protein (MCP)-1 is thought to be involved in breast carcinogenesis. We evaluated MCP-1 serum levels in patients with breast cancer (n = 135), ductal carcinoma in situ (DCIS) I-III (n = 30), benign breast lesions (n = 143) and in healthy women (n = 27). We determined the value of MCP-1 serum levels as a differentiation marker between malignant, preinvasive and benign breast diseases and as a predictive marker for the biological phenotype of breast carcinoma. Median (range) MCP-1 serum levels in patients with breast cancer, DCIS I-III, benign breast lesions and healthy women were 200 (57-692) pg/ml, 194 (58-525) pg/ml, 174 (39-529) pg/ml and 175 (67-425)…

AdultOncologymedicine.medical_specialtyCA 15-3Breast NeoplasmsBreast DiseasesBreast cancerReference ValuesInternal medicineBiomarkers TumormedicineCarcinomaHumansNeoplasm Invasivenessskin and connective tissue diseasesLymph nodeChemokine CCL2AgedRetrospective StudiesPredictive markerbusiness.industryCase-control studyGeneral MedicineMiddle AgedDuctal carcinomamedicine.diseaseCarcinoma Intraductal NoninfiltratingCell Transformation NeoplasticPhenotypemedicine.anatomical_structureCase-Control StudiesLymphatic MetastasisFemaleBreast carcinomabusinessTumor Biology
researchProduct

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by E…

2011

Background: The Gruppo Oncologico Italia Meridionale 9902 trial compared four cycles of high-dose epirubicin plus cyclophosphamide (EC) with four cycles of docetaxel (Taxotere, D) followed by four cycles of EC as adjuvant treatment of node-positive breast cancer. Patients and methods: Patients were randomly assigned to EC (E 120 mg/m 2 , C 600 mg/m 2 , arm A) for four cycles or four cycles of D (100 mg/m 2 ) followed by four cycles of EC (arm B), both regimens every 21 days. Hormone receptor-positive patients were given hormonal therapy for 5 years. Primary end point was 5-year disease-free survival (DFS). Secondary objectives were overall survival (OS) and safety. Results: There were 750 p…

AdultOncologymedicine.medical_specialtyCyclophosphamideBreast NeoplasmsDocetaxelDisease-Free SurvivalBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesProspective cohort studyCyclophosphamideSurvival analysisEpirubicinGynecologyDose-Response Relationship Drugbusiness.industryCarcinomaHazard ratioOriginal ArticlesHematologyMiddle Agedmedicine.diseaseSurvival AnalysisItalyOncologyDocetaxelLymphatic MetastasisHormonal therapyFemaleTaxoidsLymph NodesbusinessAlgorithmsmedicine.drugEpirubicinAnnals of Oncology
researchProduct

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

2019

Abstract Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-bas…

AdultOncologymedicine.medical_specialtyCyclophosphamideSettore MED/06 - Oncologia MedicaAntineoplastic AgentsBreast NeoplasmsVinorelbineDrug Administration ScheduleAntineoplastic AgentEfficacyCapecitabine03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerRetrospective StudieInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineProgression-free survivalCyclophosphamideRetrospective StudiesAgedAged 80 and overAntineoplastic Combined Chemotherapy Protocolbusiness.industryMetronomic chemotherapyVinorelbineGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerMetronomic ChemotherapySurvival RateMethotrexateTreatment Outcome030220 oncology & carcinogenesisMED/06 - ONCOLOGIA MEDICAFemaleSurgerybusinessBreast NeoplasmHumanmedicine.drugThe Breast
researchProduct

Expression Levels and Clinical-Pathological Correlations of HER2/neu in Primary and Metastatic Human Breast Cancer

2005

In this retrospective study we assessed the expression of the HER2/neu oncogene product in a series of 574 consecutive breast cancer cases, all recruited at the Maurizio Ascoli Cancer Center of Civico Hospital, in Palermo, between January 1998 and June 2003. The HER2/neu expression was evaluated using immunohistochemistry and scored from 0 to +3 as per FDA recommendations. The HER2/neu expression levels were related to the clinical-pathological features of the disease, including tumor size, nodal and menopausal status, estrogen and progesterone receptors, and hormonal or chemotherapeutic treatment. In 108 patients with a follow-up period of 3 years or more, the HER2/neu expression was also …

AdultOncologymedicine.medical_specialtyTime FactorsReceptor ErbB-2medicine.drug_classBreast NeoplasmsDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular BiologyHER2/neuBreast cancerHistory and Philosophy of ScienceInternal medicineBiomarkers TumormedicineHumansNeoplasm Metastasisskin and connective tissue diseasesPathologicalIn Situ Hybridization FluorescenceAgedRetrospective StudiesbiologyOncogenebusiness.industryGeneral NeuroscienceCancerRetrospective cohort studyMiddle Agedmedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticTreatment OutcomeEstrogenLymphatic Metastasisbiology.proteinImmunohistochemistryFemalebusinessAnnals of the New York Academy of Sciences
researchProduct

Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors

2012

The purpose of this study was to prospectively evaluate the relationship between tumor blood flow and glucose metabolism as evaluated by dynamic first-pass (18)F-FDG PET and by proliferation and endothelial pathologic markers in the setting of newly diagnosed breast cancer.Forty patients were prospectively included. Biopsy samples of each tumor were used to assess the Ki67 index of proliferation and immunostaining for CD34 (a panendothelial cell marker) and CD105 (a proliferation-related endothelial cell marker). All patients underwent (18)F-FDG PET/CT at least 1 wk after sample biopsy and before any treatment. A dynamic 2-min acquisition was performed immediately after intravenous injectio…

AdultPathologymedicine.medical_specialtyAngiogenesisStandardized uptake valueBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineMultimodal Imaging030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicineNeovascularization03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18BiopsymedicineBiomarkers Tumor[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingProspective StudiesComputingMilieux_MISCELLANEOUSAgedCell Proliferationmedicine.diagnostic_testNeovascularization Pathologicbusiness.industryEndothelial CellsBlood flowEndoglinMiddle Agedmedicine.diseasePrognosisLogistic ModelsPositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyBlood CirculationFemalemedicine.symptombusinessTomography X-Ray Computed
researchProduct

Quality of life in long-term breast cancer survivors - a 10-year longitudinal population-based study.

2013

Breast cancer survivors may experience adverse effects of cancer and/or treatment years after completion of therapy, which can considerably decrease quality of life (QoL). Little is known about the time course of QoL in breast cancer survivors beyond the fifth year post-diagnosis, when routine follow-up care has usually terminated. We therefore explored in detail whether and to what extent restrictions in breast cancer survivors persist and whether changes or aggravations in QoL occurred over time.QoL was assessed 1, 3, 5, and 10 years post-diagnosis in a population-based cohort of initially 387 female breast cancer patients from Saarland (Germany), using the EORTC QLQ-C30 and QLQ-BR23. Tim…

AdultPediatricsmedicine.medical_specialtyAdolescentCross-sectional studyPopulationBreast NeoplasmsYoung AdultBreast cancerAge DistributionQuality of lifemedicineHumansRadiology Nuclear Medicine and imagingLongitudinal StudiesSurvivorsYoung adultAdverse effecteducationAgededucation.field_of_studybusiness.industryCancersocial sciencesHematologyGeneral MedicineMiddle Agedmedicine.diseasehumanitiesCross-Sectional StudiesOncologyCohortQuality of LifeFemalebusinessActa oncologica (Stockholm, Sweden)
researchProduct

Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach

2012

Noninvasive biomarkers are urgently needed for early detection of breast cancer since the risk of recurrence, morbidity and mortality are closely related to disease stage at the time of primary surgery. In the past decade, many proteomics-based approaches were developed that utilize the protein profiling of human body fluids or identification of putative biomarkers to obtain more knowledge on the effects of cancer emergence and progression. Herein, we report on an analysis of proteins in the tear fluid from breast carcinoma patients and healthy women using a de novo proteomic approach and 25 mixed samples from each group. This study included 25 patients with primary invasive breast carcinom…

AdultProteomicsCancer ResearchProteomediagnosisPopulationBreast NeoplasmsBiologyBioinformaticsProteomicsbreast cancerBreast cancerBiomarkers TumormedicineHumansEye ProteinseducationAgedAged 80 and overeducation.field_of_studyOncogeneCase-control studyCancerArticlesGeneral MedicineMiddle Agedmedicine.diseaseOncologyCase-Control StudiesSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationProteomebiomarkerElectrophoresis Polyacrylamide GelFemaleBreast carcinomatear fluidsOncology Reports
researchProduct

Ultrasound-Guided Breast-Conservative Surgery Decreases the Rate of Reoperations for Palpable Breast Cancer

2018

The purpose of this study is to verify whether the performance of ultrasound-guided quadrantectomy (USGQ) versus palpation-guided quadrantectomy (PGQ) can reduce the incidence of positive margins and if it can change the attitude of the surgeon. A retrospective study was conducted on 842 patients underwent quadrantectomy for breast cancer, 332 of them underwent USGQ, whereas 550 underwent PGQ. The histological type of the tumors and the margin status obtained with the histological examination were compared. The histological examination of the surgical specimen showed involvement of the margins in 24/842 patients (2.85%), 22 (2.61%) of them belonged to the PGQ group, and two to the USGQ gro…

AdultReoperationmedicine.medical_specialtyBreast NeoplasmsMastectomy Segmental03 medical and health sciences0302 clinical medicineBreast cancermedicineHumans030212 general & internal medicineAgedRetrospective StudiesAged 80 and overPalpationbusiness.industryCarcinoma in situIncidence (epidemiology)Gold standardCarcinomaMargins of ExcisionRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseUltrasound guidedBreast conservative surgeryTreatment Outcome030220 oncology & carcinogenesisFemaleSurgeryRadiologyUltrasonography MammarybusinessQuadrantectomy
researchProduct

Long-term population-based risks of breast cancer after childhood cancer

2008

Previous studies have reported substantially increased risks of breast cancer among survivors of childhood cancer at 10–20 years posttreatment. Whether these excess risks are sustained beyond 40 years of age when general population incidence of breast cancer begins its steep increase is largely unknown. We quantified the risk of breast cancer in adult female survivors with considerably more survivors followed-up beyond 40 years of age than previously available. Standardized Incidence Ratios (SIR), Excess Absolute Risks (EAR), and cumulative incidence were calculated within a population-based cohort of 8,093 female survivors of childhood cancer. Poisson regression models were used to model S…

AdultRiskCancer Researchmedicine.medical_specialtyPopulationBreast NeoplasmsCohort StudiesBreast cancermedicineHumansCumulative incidenceSurvivorsRisk factorChildeducationAgededucation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseSurgeryOncologyRelative riskMultivariate AnalysisFemaleBreast diseasebusinessSEER ProgramDemographyInternational Journal of Cancer
researchProduct